GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (STU:NOVA) » Definitions » E10

Novo Nordisk A/S (STU:NOVA) E10 : €1.47 (As of Mar. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Novo Nordisk A/S E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Novo Nordisk A/S's adjusted earnings per share data for the three months ended in Mar. 2024 was €0.762. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €1.47 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Novo Nordisk A/S's average E10 Growth Rate was 16.30% per year. During the past 3 years, the average E10 Growth Rate was 14.20% per year. During the past 5 years, the average E10 Growth Rate was 13.00% per year. During the past 10 years, the average E10 Growth Rate was 14.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Novo Nordisk A/S was 27.70% per year. The lowest was 8.20% per year. And the median was 15.10% per year.

As of today (2024-05-21), Novo Nordisk A/S's current stock price is €122.50. Novo Nordisk A/S's E10 for the quarter that ended in Mar. 2024 was €1.47. Novo Nordisk A/S's Shiller PE Ratio of today is 83.33.

During the past 13 years, the highest Shiller PE Ratio of Novo Nordisk A/S was 88.29. The lowest was 25.12. And the median was 39.45.


Novo Nordisk A/S E10 Historical Data

The historical data trend for Novo Nordisk A/S's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S E10 Chart

Novo Nordisk A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.84 0.93 1.05 1.20 1.37

Novo Nordisk A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.25 1.28 1.35 1.37 1.47

Competitive Comparison of Novo Nordisk A/S's E10

For the Biotechnology subindustry, Novo Nordisk A/S's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novo Nordisk A/S's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novo Nordisk A/S's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Novo Nordisk A/S's Shiller PE Ratio falls into.



Novo Nordisk A/S E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Novo Nordisk A/S's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.762/118.4000*118.4000
=0.762

Current CPI (Mar. 2024) = 118.4000.

Novo Nordisk A/S Quarterly Data

per share eps CPI Adj_EPS
201406 0.178 99.700 0.211
201409 0.166 99.700 0.197
201412 0.169 99.400 0.201
201503 0.254 100.200 0.300
201506 0.217 100.300 0.256
201509 0.219 100.200 0.259
201512 0.217 99.800 0.257
201603 0.249 100.200 0.294
201606 0.263 100.600 0.310
201609 0.260 100.200 0.307
201612 0.233 100.300 0.275
201703 0.273 101.200 0.319
201706 0.270 101.200 0.316
201709 0.266 101.800 0.309
201712 0.226 101.300 0.264
201803 0.295 101.700 0.343
201806 0.286 102.300 0.331
201809 0.251 102.400 0.290
201812 0.237 102.100 0.275
201903 0.292 102.900 0.336
201906 0.270 102.900 0.311
201909 0.287 102.900 0.330
201912 0.248 102.900 0.285
202003 0.338 103.300 0.387
202006 0.304 103.200 0.349
202009 0.297 103.500 0.340
202012 0.270 103.400 0.309
202103 0.366 104.300 0.415
202106 0.354 105.000 0.399
202109 0.354 105.800 0.396
202112 0.320 106.600 0.355
202203 0.418 109.900 0.450
202206 0.394 113.600 0.411
202209 0.426 116.400 0.433
202212 0.405 115.900 0.414
202303 0.590 117.300 0.596
202306 0.580 116.400 0.590
202309 0.670 117.400 0.676
202312 0.659 116.700 0.669
202403 0.762 118.400 0.762

Add all the adjusted EPS together and divide 10 will get our e10.


Novo Nordisk A/S  (STU:NOVA) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Novo Nordisk A/S's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=122.50/1.47
=83.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Novo Nordisk A/S was 88.29. The lowest was 25.12. And the median was 39.45.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Novo Nordisk A/S E10 Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Novo Nordisk A/S (STU:NOVA) Business Description

Address
Novo Alle 1, Bagsvaerd, DNK, DK-2880
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.